May 31 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:
REGENERON PHARMACEUTICALS INC - LIBTAYO SHOWS 68% REDUCTION IN RISK OF DISEASE RECURRENCE OR DEATH
REGENERON PHARMACEUTICALS INC - LIBTAYO SHOWS 80% REDUCTION IN LOCOREGIONAL RECURRENCE RISK
REGENERON PHARMACEUTICALS INC - LIBTAYO SHOWS 65% REDUCTION IN DISTANT RECURRENCE RISK
REGENERON PHARMACEUTICALS INC - REGULATORY APPLICATIONS SUBMITTED IN U.S. AND EU FOR LIBTAYO
Source text: ID:nGNX7sqGyX
Further company coverage: REGN.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.